{
    "root": "358ef102-b287-cdc7-e063-6394a90aa4a6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "pantoprazole sodium",
    "value": "20250520",
    "ingredients": [
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13404"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50270"
        }
    ],
    "indications": {
        "text": "pantoprazole sodium injection indicated treatment : \u2022 gastroesophageal reflux disease ( gerd ) history erosive esophagitis ( ee ) 10 days adults . \u2022 pathological hypersecretory conditions including zollinger-ellison ( ze ) syndrome adults . limitations safety effectiveness pantoprazole sodium injection treatment upper gastrointestinal bleeding established adult pediatric patients . pediatric information approved pfizer inc. 's protonix \u00aei.v . ( pantoprazole sodium ) injection . however , due pfizer inc. 's marketing exclusivity rights , product labeled information .",
        "doid_entities": [
            {
                "text": "gastroesophageal reflux (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "gerd history ee adults : \u2022 recommended 40 mg daily intravenous injection ( least 2 minutes ) intravenous infusion ( 15 minutes ) 10 days . ( 2.1 ) \u2022 discontinue soon patient able receive oral treatment . switch appropriate oral medication within 10 days starting pantoprazole sodium injection ( 2.1 ) pathological hypersecretion conditions , including ze syndrome \u2022 recommended adult 80 mg every 12 hours intravenous injection ( least 2 minutes ) intravenous infusion ( 15 minutes ) . ( 2.2 ) \u2022 information adjust dosing individual patient needs , full prescribing information . ( 2.2 ) \u2022 switching intravenous oral formulations gastric acid inhibitors , consider pharmacodynamic action drugs ensure continuity acid suppression . ( 2.2 ) preparation instructions \u2022 full prescribing information preparation instructions indication . ( 2.3 , 2.4 )",
        "doid_entities": [
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "pantoprazole sodium injection supplied single-dose vial white off-white freeze-dried powder reconstitution containing 40 mg pantoprazole . pantoprazole sodium injection available follows : ndc number strength package size ndc 31722-204-31 40 mg/vial pantoprazole single vial ndc 31722-204-10 40 mg/vial pantoprazole 10 vials ndc 31722-204-32 40 mg/vial pantoprazole 25 vials storage handling store pantoprazole sodium injection 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protect light .",
    "adverseReactions": "\u2022 pantoprazole sodium injection contraindicated patients known hypersensitivity including anaphylaxis formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 , 5.4 ) ( 6 ) ] . \u2022 proton pump inhibitors ( ppis ) , including pantoprazole sodium injection , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Pantoprazole sodium for injection is indicated for treatment of: \n    \u2022\u00a0gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. \n    \u2022\u00a0pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults. \n  \n                     Limitations of Use\n                       The safety and effectiveness of pantoprazole sodium for injection for the treatment of upper gastrointestinal bleeding have not been established in adult or pediatric patients. \n  \n                     Pediatric use information is approved for Pfizer Inc.'s PROTONIX\n  \n   \u00aeI.V. (pantoprazole sodium) for Injection. However, due to Pfizer Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.",
    "contraindications_original": "GERD and a History of EE Adults: \u2022\u00a0The recommended dosage is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. ( 2.1 ) \u2022\u00a0Discontinue as soon as the patient is able to receive oral treatment. Switch to an appropriate oral medication within 10 days of starting pantoprazole sodium for injection ( 2.1 ) Pathological Hypersecretion Conditions, Including ZE Syndrome \u2022\u00a0The recommended adult dosage is 80 mg every 12 hours by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes). ( 2.2 ) \u2022\u00a0 For information on how to adjust dosing for individual patient needs, see the full prescribing information. ( 2.2 ) \u2022\u00a0When switching between intravenous to oral formulations of gastric acid inhibitors, consider the pharmacodynamic action of the drugs to ensure continuity of acid suppression. ( 2.2 ) Preparation and Administration Instructions \u2022\u00a0See full prescribing information for preparation and administration instructions by indication. ( 2.3 , 2.4 )",
    "warningsAndPrecautions_original": "Pantoprazole Sodium for Injection is supplied in a single-dose vial as a white to off-white freeze-dried powder for reconstitution containing 40 mg of pantoprazole. \n    Pantoprazole sodium for injection is available as follows: \n  \n                     NDC Number\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n \n  Strength\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n \n  Package Size\n                       NDC 31722-204-31\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a040 mg/vial pantoprazole\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Single vial \n    NDC 31722-204-10\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 40 mg/vial pantoprazole\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 10 vials \n    NDC 31722-204-32\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a040 mg/vial pantoprazole\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 25 vials \n  \n                     Storage and Handling\u00a0\n                       Store pantoprazole sodium for injection at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F)\n \n  [see USP Controlled Room Temperature].\u00a0\u00a0\n                     \n                     \u00a0Protect from light.",
    "adverseReactions_original": "\u2022 Pantoprazole sodium for injection is contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria\n \n  [see Warnings and Precautions (5.2, 5.4) and Adverse Reactions (\n  \n   6)].\u00a0\n \n  \u00a0 \n    \u2022 Proton pump inhibitors (PPIs), including pantoprazole sodium for injection, are contraindicated in patients receiving rilpivirine-containing products\n \n  [see Drug Interactions (\n  \n   7)].",
    "drug": [
        {
            "name": "pantoprazole sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50270"
        }
    ]
}